Answers are grounded in this paper and cite their sources.
e12504 Background: The benefit of adding adjuvant chemotherapy to endocrine therapy for hormone receptor–positive (HR+), HER2-negative (HER2-) early breast cancer remains controversial, particularly in the era of genomic risk stratification. This meta-analysis evaluated long-term survival outcomes of chemoendocrine therapy (CET) versus endocrine therapy alone (ET) in this population. Methods: PubMed, EMBASE, and the Cochrane Library were searched for randomized controlled trials (RCTs) comparing CET with ET in HR+/HER2– early breast cancer. Individual patient time-to-event data were reconstructed from published Kaplan–Meier curves. Pooled hazard ratios (HRs) for overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) were estimated using Cox frailty models. The proportional hazards assumption was tested, and restricted mean survival time (RMST) analyses quantified absolute survival differences. Results: Five RCTs including 13,866 patients met inclusion criteria. The addition of chemotherapy did not significantly improve OS (HR = 0.90; 95% CI 0.77–1.06; P = 0.221) or DDFS (HR = 0.92; 95% CI 0.74–1.15; P = 0.464). A statistically significant but clinically modest improvement was observed in IDFS (HR = 0.90; 95% CI 0.82–0.99; P = 0.035), corresponding to an RMST difference of only 0.07 years at 9 years. No violation of proportional hazards assumptions was detected. Conclusions: Among patients with HR+/HER2– early breast cancer, adjuvant chemotherapy added to endocrine therapy does not yield a significant overall survival benefit and offers only a minimal, clinically questionable improvement in invasive disease-free survival. These findings suggest that endocrine therapy alone is sufficient for most patients with low to intermediate genomic risk.
No takes yet. Share an insight, caveat, or question.
Mohib et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: